These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36794307)

  • 21. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
    Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
    Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients.
    Koike T; Harigai M; Ishiguro N; Inokuma S; Takei S; Takeuchi T; Yamanaka H; Tanaka Y
    Mod Rheumatol; 2012 Aug; 22(4):498-508. PubMed ID: 21993918
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors.
    Ekhart C; van Hunsel F; Scholl J; de Vries S; van Puijenbroek E
    Drug Saf; 2018 Jul; 41(7):677-683. PubMed ID: 29484612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immediate local and systemic hypersensitivity due to etanercept and adalimumab.
    Hansel K; Bianchi L; Tramontana M; Balato A; Scala E; Brozzi J; Stingeni L
    J Allergy Clin Immunol Pract; 2019 Feb; 7(2):726-727. PubMed ID: 30006049
    [No Abstract]   [Full Text] [Related]  

  • 26. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study.
    de Vries ST; Denig P; Ekhart C; Mol PGM; van Puijenbroek EP
    Drug Saf; 2020 May; 43(5):489-495. PubMed ID: 32048185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex differences in pharmacokinetics predict adverse drug reactions in women.
    Zucker I; Prendergast BJ
    Biol Sex Differ; 2020 Jun; 11(1):32. PubMed ID: 32503637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis.
    Santos-Moreno P; Sánchez G; Gómez D; Bello-Gualtero J; Castro C
    J Clin Rheumatol; 2016 Mar; 22(2):57-62. PubMed ID: 26886438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristic analysis of adverse reactions of five anti-TNFɑ agents: a descriptive analysis from WHO-VigiAccess.
    Li M; You R; Su Y; Zhou H; Gong S
    Front Pharmacol; 2023; 14():1169327. PubMed ID: 37554981
    [No Abstract]   [Full Text] [Related]  

  • 31. Sex-related differences in hospital admissions attributed to adverse drug reactions in the Netherlands.
    Rodenburg EM; Stricker BH; Visser LE
    Br J Clin Pharmacol; 2011 Jan; 71(1):95-104. PubMed ID: 21143505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria.
    Adisa R; Omitogun TI
    BMC Health Serv Res; 2019 Dec; 19(1):926. PubMed ID: 31796034
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015.
    Matsui T; Umetsu R; Kato Y; Hane Y; Sasaoka S; Motooka Y; Hatahira H; Abe J; Fukuda A; Naganuma M; Kinosada Y; Nakamura M
    Int J Med Sci; 2017; 14(2):102-109. PubMed ID: 28260984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature.
    Bots SH; Groepenhoff F; Eikendal ALM; Tannenbaum C; Rochon PA; Regitz-Zagrosek V; Miller VM; Day D; Asselbergs FW; den Ruijter HM
    JACC Heart Fail; 2019 Mar; 7(3):258-266. PubMed ID: 30819382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
    Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
    Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC; Teng CC; He T; Leng J; Lu CC; Walsh JA; Shah N; Harrison DJ; Tang DH; Cannon GW
    J Med Econ; 2016; 19(1):34-43. PubMed ID: 26337538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
    J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment response in rheumatoid arthritis patients starting adalimumab or etanercept with or without concomitant methotrexate.
    l'Ami MJ; Kneepkens EL; Nurmohamed MT; Krieckaert CLM; Visman IM; Wolbink GJ
    Clin Exp Rheumatol; 2017; 35(3):431-437. PubMed ID: 28079512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.